Understand the differences between sublingual ODTs and traditional tablets. Discover how orally disintegrating tablets may enhance medication delivery for certain therapies, and explore Sermorelin sublingual ODT, a needle-free alternative to injectable peptide support.
Traditional oral tablets are a common method for administering medications. However, for certain drugs, especially those sensitive to the digestive environment, alternative delivery methods can offer significant advantages.
An orally disintegrating tablet (ODT) is formulated to dissolve in the mouth without the need for water. Specifically, sublingual ODTs are placed under the tongue, allowing the medication to be absorbed directly into the bloodstream through the oral mucosa. This route can bypass the gastrointestinal tract and first-pass metabolism in the liver, potentially leading to faster and more efficient drug absorption.
Certain medications, such as peptides and hormones, can be degraded by stomach acids or enzymes, reducing their effectiveness. Sublingual administration allows these drugs to enter the bloodstream directly, potentially enhancing their bioavailability.
When drugs are absorbed through the digestive system, they often undergo first-pass metabolism in the liver, which can diminish their potency. Sublingual absorption circumvents this process, potentially leading to more consistent therapeutic effects.
Sublingual ODTs eliminate the need for water and swallowing, making them an excellent option for individuals with dysphagia or those seeking a more convenient medication regimen.
To ensure optimal absorption:
Sublingual ODTs may be particularly advantageous for:
Research supports the clinical value of ODTs and sublingual delivery methods, especially in cases where faster onset, improved adherence, or enhanced bioavailability is needed.
A study published in the International Journal of Pharmaceutics found that ODTs may offer faster onset of action compared to standard oral tablets due to their direct absorption in the mouth and shorter time to dissolution. This can be especially beneficial for medications where rapid absorption improves outcomes or comfort.
For certain peptides and protein-based therapies, oral delivery is notoriously difficult due to enzymatic degradation in the GI tract. A Journal of Controlled Release study explored sublingual delivery for peptide-based drugs and noted significantly improved absorption through the oral mucosa compared to traditional oral routes.
🔬 A study conducted by iX Biopharma demonstrated that their sublingual semaglutide wafer (iXB 401) achieved approximately 20 times greater bioavailability compared to oral semaglutide (Rybelsus®) in a rat model, highlighting the potential of sublingual routes for peptide delivery.
Recognizing the benefits of sublingual delivery, Eden offers Sermorelin ODT, a sublingual tablet designed to stimulate growth hormone production. This formulation provides a convenient, needle-free alternative to injectable therapies, with the added advantage of not requiring refrigeration.
For certain medications—especially fragile molecules like peptides—sublingual delivery offers clear, research-backed advantages. By bypassing the gastrointestinal tract and first-pass metabolism, sublingual ODTs may improve bioavailability, provide faster onset of action, and simplify daily routines.
At Eden, we believe that how you take your medication matters. Our Sermorelin ODT is a thoughtfully compounded, sublingual tablet designed to offer a needle-free, convenient option for individuals seeking growth hormone support. As always, speak with your provider to determine whether this treatment is right for your goals and needs.
Disclaimer: Sermorelin ODT is a compounded prescription medication prescribed off-label to support growth hormone production. It is not approved by the FDA for sublingual use. Statements in this article are for educational purposes only and have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult your healthcare provider before starting or changing any treatment plan.
Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.
A sublingual ODT (orally disintegrating tablet) is designed to dissolve under the tongue, enabling the medication to be absorbed directly through the mouth's mucosal lining without the need for water or swallowing.
Sublingual ODTs bypass the digestive system, while regular tablets are swallowed and absorbed through the GI tract.
Sublingual absorption can prevent degradation by stomach acids and avoid first-pass metabolism in the liver, potentially enhancing the bioavailability of specific drugs.
Place the tablet under your tongue and allow it to dissolve completely, typically within 1–2 minutes. Refrain from eating or drinking for 5–10 minutes afterward to ensure optimal absorption.
Yes, Eden offers Sermorelin ODT, a sublingual formulation of a growth hormone–stimulating peptide, providing a needle-free alternative to injections.
Cilurzo, Francesco, et al. “Orodispersible Dosage Forms: Biopharmaceutical Improvements and Regulatory Requirements.” Drug Discovery Today, vol. 23, no. 2, Feb. 2018, pp. 251–259, https://doi.org/10.1016/j.drudis.2017.10.003.
Wu, Jiamin, et al. “Systemic Delivery of Proteins Using Novel Peptides via the Sublingual Route.” Journal of Controlled Release, vol. 368, 1 Apr. 2024, pp. 290–302, https://doi.org/10.1016/j.jconrel.2024.02.042.
Cilurzo, Francesco, et al. “Orodispersible Dosage Forms: Biopharmaceutical Improvements and Regulatory Requirements.” Drug Discovery Today, vol. 23, no. 2, Feb. 2018, pp. 251–259, https://doi.org/10.1016/j.drudis.2017.10.003.
FB, Abay, and Ugurlu T. “Orally Disintegrating Tablets: A Short Review.” Journal of Pharmaceutics and Drug Development, vol. 3, no. 3, June 2015, https://doi.org/10.15744/2348-9782.3.303.
IX Biopharma SL Semaglutide (IXB 401) Technical Report a Single-Dose Pharmacokinetic Study of a Novel Sublingual Semaglutide Wafer in Rats. https://www.ixbiopharma.com/wp-content/uploads/2024/11/iX401_Semaglutide_Rat_PK-Study-12-11-24_v6-002.pdf
